Trial Profile

A Prospective Non-interventional Study Investigating the Treatment Effect of Tresiba in Adult Patients With Type 2 Diabetes in Saudi Arabia

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 28 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin degludec (Primary)
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms UPDATES
Sponsors Novo Nordisk

Most Recent Events

22 Nov 2022 Primary endpoint (Change in HbA1c (mmol/mol)) has been met according to results published in the Advances in Therapy.
22 Nov 2022 Primary endpoint (Change in glycated haemoglobin HbA1c (percentage)has been met according to results published in the Advances in Therapy
22 Nov 2022 Results (n=561)assessing Glycaemic Control in People with Type 2 Diabetes Treated with Insulin Degludec published in the Advances in Therapy

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com